New cancer drug EVT801 tested in humans for first time
NCT ID NCT05114668
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested an experimental drug called EVT801 in 32 adults with advanced solid tumours that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose to use in future studies. Participants took EVT801 capsules by mouth daily.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EVT801 (an experimental drug taken orally as a capsule)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumours that have not responded to other therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 32 participants. Its main goal is safety and dosing, not effectiveness. Many early-stage drugs do not go on to become approved treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Léon Bérard
Lyon, 69373, France
-
Institut Universitaire du Cancer Toulouse - Oncopole
Toulouse, 31059, France